{Reference Type}: Journal Article
{Title}: Therapeutic applications of AS1411 aptamer, an update review.
{Author}: Yazdian-Robati R;Bayat P;Oroojalian F;Zargari M;Ramezani M;Taghdisi SM;Abnous K;
{Journal}: Int J Biol Macromol
{Volume}: 155
{Issue}: 0
{Year}: Jul 2020 15
{Factor}: 8.025
{DOI}: 10.1016/j.ijbiomac.2019.11.118
{Abstract}: Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus. However, in several cancers, nucleolin is highly expressed both intracellularly and on the cell surface. So, it is considered as a potential target for the diagnosis and cancer therapy. Targeting nucleolin by compounds such as AS1411 aptamer can reduce tumor cell growth. In this regard, interest has increased in nucleolin as a molecular target for overcoming cancer therapy challenges. This review paper addressed recent progresses in nucleolin targeting by the G-rich AS1411 aptamer in the field of cancer therapy mainly over the past three years.